[Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)].
Higher levels of serum phosphate are associated not only with progression of secondary hyperparathyroidism but also adverse cardiovascular outcomes, such as ectopic calcifications, cardiovascular events its death. The treatments of hyperphosphatemia with phosphate binders were shown to be effective on a risk factor for cardiovascular disease and mortality on hemodialysis patients.
Imanishi
Yasuo
Y
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000209:etiology; D002614:Chelating Agents / Q000627:therapeutic use; D002908:Chronic Disease; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000209:etiology; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology / Q000401:mortality*; D010710:Phosphates / Q000097:blood / Q000378:metabolism*; D011073:Polyamines / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects / Q000401:mortality; D012307:Risk Factors; D000069603:Sevelamer
D015415:Biomarkers; D002614:Chelating Agents; D010710:Phosphates; D011073:Polyamines; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000069603:Sevelamer